A preventive effect of unfractionated heparin on post-ERCP pancreatitis is suggested by positive effects on laboratory markers

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 168-173

  Ung, Kjell Arne ^a   Rydberg, Lars ^a   Modin, Stefan ^a   Kylebäck, Anders ^a   Modin, Marina ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ERCP; Heparin; Pancreatitis; Prophylaxis; Surrogate marker; Unfractionated

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; HEPARIN; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOLOGICAL MARKERS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PANCREATIC FUNCTION TESTS; PANCREATITIS; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79954991377     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory CNickl N: Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383-393.
2. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, et al: Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-918. (Pubitemid 26314443)
3. Sherman S, Lehman GA: ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991; 6:350-367.
4. Abdel Aziz AM, Lehman GA: Pancreatits after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007; 13:265-268.
5. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, et al: Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-434. (Pubitemid 33661145)
6. Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, Riley SA, et al: Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39:793-801.
7. Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, et al: Risk Factors for Post-ERCP Pancreatitis: A Prospective Multicenter Study. Am J Gastroenterol 2006; 101:139-147.
8. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, Muehldorfer S, et al: Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55:476-483.
9. Bai Y, Gao J, Zhang W, Zou DLi Z: Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28:557-564.
10. Bang UC, Nojgaard C, Andersen PK, Matzen P: Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther 2009; 29:1078-1085.
11. Andriulli A, demente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, Leandro G, Leo P, et al: Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-495.
12. Binmoeller KB, Harris AG, Hastier P, Dumas R, Delmont JP: Octreotide and ERCP-induced pancreatitis: beneficial or harmful? Am J Gastroenterol 1993; 88:1291.
13. Hardt PD, Kress O, Fadgyas T, Doppl W, Schnell-Kretschmer H, Wusten O, Klor HU: Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res 2000; 5:165-170.
14. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al: Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52:1768-1773. (Pubitemid 37510401)
15. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C: Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124:1786-1791. (Pubitemid 36666775)
16. Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR: Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol 2008; 23:11-16.
17. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M: Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007; 102:978-983. (Pubitemid 46698240)
18. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD: A meta-analysis of NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008.
19. Wagh MS, Sherman S: Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail. Am J Gastroenterol 2007; 102:984-986. (Pubitemid 46698238)
20. Dlugosz J, Bajko K, Gabryelewicz A: The effect of heparin on lysosomes of the dog pancreas during acute experimental pancreatitis. Exp Pathol (Jena) 1979; 17:237-242. (Pubitemid 9227782)
21. Dobosz M, Hac S, Mionskowska L, Dobrowolski S, Wajda Z: Microcirculatory disturbances of the pancreas in cerulein-induced acute pancreatitis in rats with reference to L-arginine, heparin, and procaine treatment. Pharmacol Res 1997; 36:123-128. (Pubitemid 27460409)
22. Dobosz M, Wajda Z, Hac S, Mysliwska J, Mionskowska L, Bryl E, Roszkiewicz A, Mysliwski A: Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Forum (Genova) 1998; 8:303-310. (Pubitemid 28464355)
23. Gabryelewicz A, Kosidlo S, Prokopowicz J, Podkowicz K: Does heparin modify protease-antiprotease balance in acute experimental pancreatitis in rats. Hepatogastroenterology 1986; 33:79-82. (Pubitemid 16119919)
24. Hackert T, Werner J, Gebhard M, MKlar E: Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis. Surgery 2004; 135:131-138. (Pubitemid 38130763)
25. Kosidlo S, Gabryelewicz A, Prokopowicz J, Podkowicz K: Pancreatic proteolytic and inhibitory activity during acute experimental pancreatitis in rats with reference to heparin treatment. Mater Med Pol 1986; 18:136-143. (Pubitemid 17224184)
26. Toulon P, Chadeuf G, Bouillot JL, Amiral J, Cambillau M, Sultan Y, Aiach M: Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man. Eur J Clin Invest 1991; 21:303-309.
27. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A: Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101:877-889. (Pubitemid 28096085)
28. Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Troger M, Hochberger J, et al: Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:606-613. (Pubitemid 38609687)
29. LaFerla G, Gordon S, Archibald M, Murray WR: Hyperamylasaemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas 1986; 1:160-163. (Pubitemid 17019916)
30. Mann DV, Kalu P, Foulds S, Edwards R, Glazer G: Neutrophil activation and hyperamylasaemia after endoscopic retrograde cholangiopancreatography: potential role for the leukocyte in the pathogenesis of acute pancreatitis. Endoscopy 2001; 33:448-453. (Pubitemid 32586454)
31. Silverman WB, Thompson RA: Management of asymptomatically/minimally symptomatic post-ERCP serum liver test elevations: first do no harm. Dig Dis Sci 2002; 47:1498-1501. (Pubitemid 34753926)
32. Eriksson BI, Kalebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B: Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991; 73:484-493.
33. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, Panes J: Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000; 47:88-96.
34. Lever R, Hoult JR, Page CP: The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533-540. (Pubitemid 30083875)
35. Rais O: Heparin treatment of peritenomyosis (peritendinitis) crepitans acuta. A clinical and experimental study including the morphological changes in peritenon and muscle. Acta Chir Scand Suppl 1961; Suppl 268:1-88.
36. Renda G, Di Pillo R, D'Alleva A, Sciartilli A, Zimarino M, De Candia E, Landolfi R, et al: Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica 2007; 92:366-373. (Pubitemid 350143546)